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Early Versus Delayed Enalapril in Patients With Left Ventricular Systolic Dysfunction:
Impact on Morbidity and Mortality 15 Years After the SOLVD Trial
To the Editor: The Studies Of Left Ventricular Dysfunction
(SOLVD) trial showed that enalapril, an angiotensin-converting
enzyme (ACE) inhibitor, reduced morbidity and mortality in
patients with ejection fractions 35% (1,2), including the risks of
myocardial infarction and unstable angina (3). Recently, the
Extended SOLVD (X-SOLVD) trial indicated that the mortality
benefit continued to accrue for a decade beyond the original trial
period (4). In this longest follow-up of any heart failure random-
ized clinical trial, we compared the 15-year post-trial mortality and
serious cardiovascular (CV) morbidity among patients who were
initially randomized to either enalapril or placebo, offering an
opportunity to assess the clinical consequences of delaying the
initiation of ACE inhibitor therapy.
The initial study cohort consisted of all 558 Belgian patients
among the 6,797 subjects enrolled in the prevention and treatment
arms of the SOLVD trial. At trial close-out, 433 patients (97 in
treatment and 336 in prevention arms) were still alive (218 in
enalapril and 215 in placebo groups) and received open-label
enalapril therapy (Table 1). Post-trial morbidity and mortality
status was established by direct or telephone contact with patients,
relatives, or physicians involved in their care and through reviews
of the patients’ medical records. Each patient gave informed
consent, and the study protocol was approved by the local
institutional review board. The primary end point was the com-
posite outcome of death or serious CV morbid events, defined as
development of heart failure, myocardial infarction, or stroke, or
need for heart transplant, device therapy (pacemaker, implantable
cardioverter-defibrillator), or myocardial revascularization (coro-
nary angioplasty, bypass surgery). Causes of death, available for all
subjects, were classified using the International Classification of
Diseases-Ninth Revision (ICD-9) code. Morbidity data were only
available for subjects still alive at last contact.
Statistical analysis was performed on an intention-to-treat basis
according to the drug therapy assigned at the time of randomiza-
tion in the SOLVD trial. The composite outcome was defined
hierarchically based on the most serious adverse event. Among
subjects who had died during the extended follow-up, death was
recorded as the most serious adverse outcome event. In compari-
son, among subjects who were still alive at last contact, the first
morbid event was recorded as the most serious adverse outcome
event. Time-to-event curves for morbidity and mortality during
the extended follow-up were compared between enalapril and
placebo groups using the generalized Wilcoxon test. Hazard ratios
were calculated based on Cox regression models. The Breslow-Day
test was used to assess for homogeneity of treatment effect from
early enalapril therapy across the two arms of the SOLVD trial.
The median duration of follow-up was 15.5 years from ran-
domization and 12.2 years from study close-out. No patients were
lost to follow-up. Among the 131 subjects who were alive and had
not undergone heart transplantation at last contact, no difference
was observed in the proportion taking ACE inhibitors after the
trial between the enalapril and placebo groups (85% vs. 79%, p 
0.40).
Fewer deaths (138 vs. 150) occurred among patients treated
early with enalapril as compared with placebo (63% vs. 70%,
Wilcoxon p 0.01) (Fig. 1), corresponding to a 6.5% absolute risk
reduction in mortality. This benefit was apparent within the first
year after trial close-out and persisted for the entire duration of
follow-up. The combined risk of death or serious CV morbid event
during the extended follow-up was significantly lower in enalapril
(177 of 218 [81%]) than in placebo patients (188 of 215 [87%])
(Wilcoxon p  0.008), corresponding to a 6.2% absolute risk
reduction in favor of early enalapril therapy. The benefits of early
enalapril therapy were similar between patients enrolled in the
prevention and the treatment arm of the SOLVD trial (tests of
homogeneity, p 0.73 for death and p 0.39 for combined death
or serious CV morbid event).
Among patients still alive at follow-up, early enalapril therapy
was associated with a 14% absolute reduction (10 of 80 [12%] vs.
17 of 65 [26%]; Wilcoxon p  0.04) and a 57% relative reduction
in nonfatal cardiac ischemic events, as defined by the occurrence of
myocardial infarction or the need for coronary angioplasty or
bypass surgery (hazard ratio 0.43, 95% CI 0.20 to 0.95, p  0.04).
Our data also showed that the risk of death or nonfatal cardiac
ischemic events was significantly lower among patients who
received enalapril early as in-trial therapy than among those who
only received enalapril after the trial ended (148 of 218 [68%] vs.
167 of 215 [78%]; Wilcoxon p  0.001).
Excluding heart transplantations, 61 patients remained free of
any adverse CV event during the extended follow-up, as compared
Table 1. Baseline Characteristics of Patients in Post-Trial
Follow-Up According to Randomized Drug Therapy
Characteristics
Enalapril
(n  218)
Placebo
(n  215) p
Age* (yrs) 60 61 0.20
Ejection fraction* (%) 29 29 0.58
Trial arm 0.34
Prevention 165 (76%) 171 (80%)
Treatment 53 44
Gender 0.37
Male 183 (84%) 187 (87%)
Female 35 28
NYHA functional class 0.18
I 81 (37%) 78 (36%)
II 105 (48%) 117 (54%)
III–IV 32 20
Etiology 0.22
Ischemic 167 (77%) 175 (81%)
Others 51 40
Prior hypertension 0.59
Yes 45 (21%) 40 (19%)
No 173 175
Prior diabetes mellitus 0.38
Yes 17 (8%) 22 (10%)
No 201 193
*Median values.
NYHA  New York Heart Association.
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with 358 who had at least one adverse event. Considering the
baseline characteristics, event-free patients were younger (54 vs. 61
years, p  0.0001), had a lower functional class (New York Heart
Association functional class I to II 97% vs. 87%, p  0.003), and
had a higher ejection fraction (32% vs. 29%, p  0.002) at
randomization. Event-free patients were also more likely to receive
in-trial enalapril therapy than placebo (38 [62%] vs. 173 [48%],
p  0.04).
Our data indicated that early enalapril therapy reduced death
and serious CV morbid events at 15 years in the Belgian SOLVD
cohort. Specifically, at the end of this extended follow-up, a
significant risk reduction in mortality was observed among patients
treated early with enalapril compared with placebo, confirming our
previous findings in the X-SOLVD trial. One mechanism that
could explain these clinical benefits is the beneficial effect of
enalapril on left ventricular remodeling and diastolic properties (5).
Furthermore, prevention of early nonfatal cardiac ischemic events
by enalapril during in-trial treatment (3) may lead to a late benefit
in mortality. The original SOLVD data showed that enalapril
reduced the incidence of cardiac ischemic events. The present
study extended this finding by showing that the risk of death or
nonfatal cardiac ischemic events remained significantly lower in
the early enalapril group than in the delayed group. This suggests
that earlier treatment initiation may confer long-term protection
against atherosclerotic complications by a sustained beneficial
effect on plaque stability and vascular remodeling (3,6). Moreover,
our data suggested that on the event-free patients, middle-aged
asymptomatic subjects derived the most protection from early
enalapril therapy. This observation confirms the need to initiate
enalapril without delay in patients with reduced ejection fractions,
even in the absence of symptoms. However, we could not exclude
that genetic variations might also explain this excellent long-term
evolution.
In conclusion, in the 15-year follow-up of the Belgian SOLVD
cohort, early enalapril therapy prevented late deaths and serious
CV morbid events beyond the original trial period. Our data also
refuted the suggestion that ACE inhibitors in patients with
asymptomatic or minimally symptomatic ventricular dysfunction
would not confer any long-term benefit except for masking the
development of heart failure. Our study showed the importance of
starting ACE inhibitor therapy as early as possible in patients with
left ventricular systolic dysfunction to avoid any delay resulting in
any significant loss of benefits years later.
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Short QT Interval and Atrial Fibrillation in Patients Without Structural Heart Disease
To the Editor: The short QT syndrome is a newly described
clinical entity characterized by the presence of a short QT interval
associated with cardiac tachyarrhythmias in otherwise healthy
individuals. A genetic basis has been identified linking the disease
to mutations in KCNH2 in the familial forms and a mutation in
KCNQ1 in a sporadic form of the disease (1). The description of
a novel, de novo gain of function mutation in KCNQ1, responsible
for atrial fibrillation (AF) and short QT syndrome in utero,
indicates that gain of function mutations in KCNQ1 channels can
shorten the duration of both ventricular and atrial action potentials
(2), which could account for the high incidence of AF in patients
with short QT syndrome (3). Atrial fibrillation can occur in the
Figure 1. Kaplan-Meier mortality curves during the post-trial period
between patients randomized to enalapril and to placebo. The data showed
that the benefit in the enalapril group was apparent within the first year
after trial close-out and persisted for the entire duration of the extended
follow-up (Wilcoxon p  0.01).
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